Predictors of flares in Systemic Lupus Erythematosus: Preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Patients with Systemic Lupus Erythematosus (SLE) may experience flare of disease activity. The aim of this study was to assess incidence, clinical features and predictors of flares, focusing on the relationship with serially assessed anti-double stranded DNA antibodies (anti-dsDNA) serum levels by Farr assay and pre-emptive therapeutic approaches of flares, through the analysis of a monocentric cohort of SLE patients and a literature review. Clinical and laboratory data of 120 out of 334 SLE patients, fulfilling inclusion criteria for enrolment and followed up between 1997 and 2012, were retrospectively collected. For the purposes of the study, a flare was defined as any new SLE manifestation or worsening of a pre-existing manifestation resulting in change of therapy. A review of the literature was performed searching for articles published between 1980 and 2015. Over a median (IQR) follow-up of 5.9 (3.0-8.9) years, 87 flares were recorded in 59 (49%) patients. The estimated incidence rate was 0.11 flare per patient-year, at the low-end of values reported in literature (0.19-1.76 patient-year). In our cohort, fluctuating anti-dsDNA serum levels were associated with flare development whereas precautionary change of therapy in presence of increased anti-dsDNA levels >50% was effective in preventing flares (p<0.05). Results from literature review highlighted that increasing anti-dsDNA and precautionary change of therapy were predictive and pre-emptive of flares, respectively, in some studies but not in others. Differences in laboratory methods and patient selection, in terms of ethnicity, disease duration, and background therapy are likely to be crucial in determining discordant results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Petri, M., Orbai, A., Alarcón, G. S., Gordon, C., Merrill, J. T., Fortin, P. R., Bruce, I. N., Isenberg, D., Wallace, D. J., Nived, O., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34473 · Cited by 5,322
Bertsias, G., Ioannidis, J. P. A., Boletis, J., Bombardieri, S., Cervera, R., Dostal, C., Font, J., Gilboe, I. M., Houssiau, F., Huizinga, T., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.070367 · Cited by 762
Ter Borg, E. J., Horst, G., Hummel, E. J., Limburg, P. C., & Kallenberg, C. G. M. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330505 · Cited by 572
Prevention of relapses in systemic lupus erythematosus
Bootsma, H., Spronk, P., de Boer, G., Limburg, P., Kallenberg, C., Derksen, R., Wolters-Dicke, J., Gmelig-Meyling, F., Kater, L., & Hermans, J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90114-0 · Cited by 290
Guidelines for immunologic laboratory testing in the rheumatic diseases: Anti‐DNA antibody tests
Kavanaugh, A. F., Solomon, D. H., & The American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) · Arthritis Care & Research · doi:10.1002/art.10558 · Cited by 225
A surge in anti-dsDNA titer predicts a severe lupus flare within six months
Pan, N., Amigues, I., Lyman, S., Duculan, R., Aziz, F., Crow, M., & Kirou, K. (2014) · Lupus · doi:10.1177/0961203313515763 · Cited by 59
Cited by
de Leeuw, K., Bungener, L., Roozendaal, C., Bootsma, H., & Stegeman, C. A. (2017) · Rheumatology · doi:10.1093/rheumatology/kex314 · Cited by 19
Lakota, K., Švec, T., Kveder, T., Sodin-Šemrl, S., Žigon, P., Ambrožič, A., Ogrič, M., Markez, S., Božič, B., Tomšič, M., et al. (2019) · Clinical Rheumatology · doi:10.1007/s10067-018-4271-3 · Cited by 10
He, S., Wu, X., Li, L., Jiang, K., He, Q., & Xie, L. (2023) · Lupus · doi:10.1177/09612033231179888 · Cited by 2
Metadata
- Authors
- Floris, A., Piga, M., Cauli, A., & Mathieu, A.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2016-07
- Volume
- 15
- Issue
- 7
- Pages
- 656-663
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2289244511
- Cited by
- 74
- References
- 6
- FWCI
- 8.73
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.